VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease.

Bodil WeidungEva-Stina HemmingssonJan OlssonTorbjörn SundströmKaj BlennowHenrik ZetterbergMartin IngelssonFredrik ElghHugo Lövheim

Published in: Alzheimer's & dementia (New York, N. Y.) (2022)

Four weeks of high-dose valacyclovir treatment was safe, tolerable, and feasible in early-stage AD. Our findings may guide future trial design.

Keyphrases